# US 7,465,554 B2 · Gene encoding a multidrug-resistance human P-glycoprotein homologue on chromosome 7p15-2 and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,465,554 B2
- Document ID: US7465554B2
- Status: Granted
- Kind: B2
- Application number: 10/952,328
- Filed: 2004-09-29
- Published: 2005-03-03
- Granted: 2008-12-16
- Earliest claimed: 2000-06-05
- Assignees: The Brigham and Women's Hospital, Inc.
- Inventors: Markus H. Frank; Mohamed H. Sayegh
- Web page: https://patentgrep.com/patent/US7465554B2

## CPC

- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- A61K 39/0011: {Cancer antigens}
- A61P 37/02: Immunomodulators
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to an MDR family P-glycoprotein located on human chromosome 7p15-21, polynucleotide sequences encoding this P-glycoprotein and fragments thereof. This gene is utilized in methods for assessing cancer cell susceptibility to therapies directed against multidrug resistance, and for the design of diagnostic and therapeutic methods relating to cancer multidrug resistance. The invention also relates to methods for determining whether a test compound may inhibit multidrug resistance.

## Claims

### Claim 1

A method of determining whether a cancer cell expresses a gene that contributes to multidrug resistance, comprising selecting a cancer cell and assaying said cancer cell for the expression of the protein of SEQ ID NO:2 and associating the expression of the protein of SEQ ID NO:2 with the cancer cell having multidrug resistance.

### Claim 2 (depends on 1)

the method of claim 1, wherein expression of said protein is determined using an antibody that preferentially binds to a protein with the sequence of SEQ ID NO:2.

### Claim 3 (depends on 2)

The method of claim 2, wherein said antibody is a polyclonal antibody.

### Claim 4 (depends on 2)

The method of claim 2, wherein said antibody is a monoclonal antibody.

### Claim 5 (depends on 1)

The method of claim 1, wherein expression of said protein is determined using an immunoassay.

### Claim 6 (depends on 5)

The method of claim 5, wherein said immunoassay is a radioimmunoassay.

### Claim 7 (depends on 5)

The method of claim 5, wherein said immunoassay is an immunometric assay.

### Claim 8 (depends on 2, 3, 4, 5, 6, 7)

The method of any one of claims 2-7, wherein said cancer cell is a melanoma cell.